AzTrials
AzTrials

Spinal Muscular Atrophy Type INCT06632730

Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

An observational study of Spinal Muscular Atrophy Type I and Spinal Muscular Atrophy Type II, run by Novartis at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals). Read more about this study

Who is it for?
Ages Up to 14 years
How many people
69 participants
Where
1 siteUnited States
Study dates
5 Jul 2023to 20 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 14 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: This was a retrospective, noninterventional cohort study.

Who may be able to join

  • Patients diagnosed with SMA type I or SMA type II.
  • Patients with medical records available in the hospital.
  • Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.

Who cannot join

  • Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Novartis Pharmaceuticals

    East Hanover, New Jersey, 07936

Other trials in United States

About this study

Official title: Therapeutic Management and Current Situation Related to the Use of Resources and Costs of Spinal Muscular Atrophy (SMA) in Spain: A Retrospective, Multicenter Analysis Based on Medical Record Review. TREaSURE Study

An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).

Medical subject headings
Spinal Muscular Atrophies of Childhood

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06632730
Study groupRoleWhat they receive
Spinal Muscular Atrophy (SMA) CohortPediatric patients with SMA type I, SMA type II, or presymptomatic SMA.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cost per Year of Use of Resources for Medical Visits

    Medical visits included:

    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonologist
    • Cardiologist
    • Physical therapist
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other specialists
    • Total medical visits
    • Hospital emergency room visits
    • Outpatient emergency room visit
    • Hospitalizations/Admissions to ward
    • Hospitalizations due to admissions to the intensive care unit (ICU)
    • Total hospitalizations (ward and ICU)
    • Therapy session separately from medical visits

    Measured: Up to 12 months

  2. Costs per Year of Use of Resources for Medical Tests

    Medical tests included:

    • Blood count
    • Vitamin D test
    • Blood creatine kinase test
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis
    • Total additional tests

    Measured: Up to 12 months

  3. Cost per Year of Use of Resources for Treatment

    Treatments included:

    • Nusinersen (loading and maintenance dose)
    • Total Nusinersen
    • Risdiplam
    • Onasemnogene abeparvovec
    • Total treatments for SMA
    • Palivizumab
    • Influenza vaccine
    • Meningococcal vaccine
    • High protein shakes
    • Total adjuvant treatments
    • Total treatments

    Measured: Up to 12 months

Secondary outcomes (46)
  1. Number of Patients per Sociodemographic Category

    Sociodemographics included:

    • Biological sex
    • Dead patients
    • Growth percentiles for growth charts (3%, 4-15%, 16-50%, 51-85%, 86-97%, greater than 97%)
    • Patient's cohabitants (father, mother, both parents, brother(s), sister(s), other relatives)
    • Patient's caregiver (father, mother, both parents, brother(s), sister(s), other relatives)
    • Patient's primary caregiver (father, mother, both parents, brother(s), sister(s), other relatives)

    Measured: Baseline

  2. Sociodemographic: Age

    • Age at the time of data collection
    • Age of onset of SMA symptoms
    • Age at clinical diagnosis of SMA
    • Age of death

    Measured: Baseline

  3. Sociodemographic: Weight

    Measured: Baseline

  4. Sociodemographic: Height

    Measured: Baseline

  5. Sociodemographic: Body mass index (BMI)

    Measured: Baseline

  6. Number of Patients per Clinical Characteristic Category

    Clinical characteristics included:

    • Anti-adeno-associated virus serotype 9 (AAV9) antibody titer test
    • Neonatal screening for SMA together with other screening tests
    • Prenatal or perinatal SMA diagnosis
    • Ventilatory support
    • Patient with scoliosis
    • Patient with scoliosis surgery
    • Patients with a chair for scoliosis
    • Total or partial cost of the chair for scoliosis borne by the family
    • Patients still use a chair for scoliosis at the time of data collection
    • Patients with back brace
    • Total or partial cost of the back brace borne by the family
    • Patient with hip dislocations or subluxations
    • Head control
    • Relevant medical record
    • End of ventilatory support

    Measured: Baseline

  7. Clinical Characteristic: Age From Which Information Was Available

    Measured: Baseline

  8. Clinical Characteristic: Time From Onset of Symptoms to Diagnosis

    Time intervals included:

    • Less than 1 month
    • 1 to 3 months
    • 4 to 6 months
    • 7 to 18 months
    • More than 18 months

    Measured: Baseline

  9. Clinical Characteristic: Number of Patients Categorized by International Classification of Diseases (ICD) Code

    ICD codes included:

    • ICD-9 335.1: Spinal muscular atrophy
    • ICD-9: 335.1: Spinal muscular amyotrophy, unspecified
    • ICD-9 335.11: Kugelberg-Welander disease
    • ICD-10 G12.1: Other hereditary spinal muscular atrophies
    • ICD-10 G12.25: Progressive spinal muscular atrophy
    • ICD-10 G12.8: Other spinal muscular atrophies and related syndromes
    • ICD-10 G12.9: Spinal muscular atrophy, unspecified

    Measured: Baseline

  10. Clinical Characteristic: Number of Patients Categorized by Type of Diagnosis of Muscle Atrophy

    Diagnosis types included:

    • Clinical suspicion and subsequent patient referral for genetic confirmation
    • Genetic diagnosis

    Measured: Baseline

  11. Clinical Characteristic: Number of Patients Categorized by Type of Mutation

    Mutations included:

    • Biallelic deletion of exons
    • Biallelic deletion of exon 7
    • Biallelic deletion of exons 7 and 8
    • Compound heterozygous mutation
    • Point mutation and deletion of exons 7 and 8
    • Biallelic point mutation

    Measured: Baseline

  12. Clinical Characteristic: Number of Patients Categorized by Survival of Motor Neuron 2 (SMN2) Gene Copy Number

    SMN2 copy numbers: 0, 1, 2, 3, 4, and greater than 4.

    Measured: Baseline

  13. Clinical Characteristic: Number of Patients Categorized by SMA-associated Comorbidities

    SMA-associated comorbidities included:

    • Chronic lung disease
    • Swallowing impairment
    • Malnutrition
    • Hypoxic encephalopathy
    • Relapsing obstructive bronchial syndrome
    • Recurrent pneumonia
    • Sleep apnea-hypopnea syndrome
    • Epilepsy
    • Hip dysplasia
    • Obesity
    • Respiratory compromise
    • Thorax deformity
    • Scoliosis
    • Other

    Measured: Baseline

  14. Clinical Characteristic: Number of Patients Categorized by Family History of SMA

    Family history categories included:

    • Yes
    • No
    • Mother
    • Father
    • Both parents
    • Brothers and sisters
    • Other

    Measured: Baseline

  15. Clinical Characteristic: Number of Patients Categorized by Type of Ventilatory Support

    Types of ventilatory support included:

    • Invasive (hospital and outpatient)
    • Non-invasive (hospital and outpatient)

    Measured: Baseline

  16. Clinical Characteristic: Number of Patients Categorized by Reason of Ventilatory Support Regimen

    Reasons of ventilatory support included:

    • Preventive intent
    • Therapeutic intent

    Measured: Baseline

  17. Clinical Characteristic: Duration of Ventilatory Support

    Measured: Baseline

  18. Clinical Characteristic: Number of Patients With Nutritional Supplementation

    Measured: Baseline

  19. Clinical Characteristic: Number of Patients Categorized by Type of Administration of Nutritional Supplementation

    Types of administration included:

    • By mouth
    • Through a feeding tube
    • Both (mouth and feeding tube)
    • Through gastrostomy

    Measured: Baseline

  20. Clinical Characteristic: Number of Patients Categorized by Type of Nutritional Supplementation Received by Mouth

    Types of nutritional supplementation included liquid thickeners (corn starch and Nutilis Clear thickener, neutral taste, Nutricia) and nutrition supplements (Resource shakes, High protein shakes, Ensure Junior drink, Infatrini, Pediasure Complete, RESOURCE C, Vitamin D, Fortini high protein shakes, protein shakes, Pediasure, Resource with fiber, Resource protein).

    Measured: Baseline

  21. Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements by Mouth

    Measured: Baseline

  22. Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements Through a Feeding Tube

    Measured: Baseline

  23. Clinical Characteristic: Duration of Nutritional Supplementation Received by Mouth and Through a Feeding Tube or Gastrostomy

    Measured: Baseline

  24. Clinical Characteristic: Number of Surgeries for Patients With Scoliosis

    Measured: Baseline

  25. Clinical Characteristic: Number of Patients Categorized by Type of Surgery Received for Scoliosis

    Types of surgeries included:

    • Growing rods lengthening
    • Dorsal/lumbar dorsal arthrodesis
    • Growing rods

    Measured: Baseline

  26. Clinical Characteristic: Number of Patients Categorized by Type of Joint Contracture

    Types of joint contractures included proximal and distal.

    Measured: Baseline

  27. Clinical Characteristic: Number of Patients Who Reached Each Motor Development Milestone

    Developmental Milestones:

    • Sitting independently or with support
    • Standing independently or with support
    • Walking independently or with support
    • Crawling with the elbows, belly crawl, or with hands and knees

    Measured: Baseline

  28. Clinical Characteristic: Number of Patients Categorized by Relevant Surgical History in Addition to Scoliosis Surgery Related to SMA Categorized by Type of Surgery

    Surgeries included:

    • Mouth surgery
    • Tracheostomy
    • Surgery for gastrostomy
    • Tenotomy
    • Other

    Measured: Baseline

  29. Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year

    Healthcare visits included:

    • General
    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonology
    • Cardiologist
    • Physical therapy
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other experts
    • Emergency Room
    • Related to therapy

    Measured: Up to 12 months

  30. Total Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year

    Measured: Up to 12 months

  31. Number of Scheduled and Unscheduled SMA-related Medical Visits

    SMA-related medical visits included:

    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonologist
    • Cardiologist
    • Physical therapist
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other specialists

    Measured: Up to 12 months

  32. Number of SMA-related Emergency Room Visits

    SMA-related emergency room visits included outpatient and hospital visits.

    Measured: Up to 12 months

  33. Number of SMA-related Hospitalizations

    SMA-related hospitalizations included visits to day hospital, admissions to ward, intensive care unit admissions.

    Measured: Up to 12 months

  34. Number of Patients Categorized by Reason for Hospitalization

    Hospitalization included admission to ward. Reason for hospitalization included related to treatment and not related to treatment.

    Measured: Up to 12 months

  35. Number of Patients Categorized by Reason for Admission to Intensive Care Unit (ICU)

    Reason for admission to ICU included related to treatment and not related to treatment.

    Measured: Up to 12 months

  36. Number of Patients With a Multidisciplinary Follow-up

    Measured: Up to 12 months

  37. Number of Patients Categorized by Medical Areas Involved in Follow-up

    Medical areas included:

    • Pulmonology
    • Endocrinology/nutrition
    • Physical therapy
    • Rehabilitation
    • Logopedics
    • Thoracic surgery
    • Orthopedics
    • Other

    Measured: Up to 12 months

  38. Number of Patients Categorized by Type of Additional Tests Needed

    Additional tests included:

    • Blood count
    • Vitamin D test
    • Blood creatine kinase test
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis

    Measured: Up to 12 months

  39. Number of Times Each Additional Test Was Performed

    Additional tests included:

    • Blood count
    • Vitamin D
    • Blood creatine kinase
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis

    Measured: Up to 12 months

  40. Total Additional Tests

    Measured: Up to 12 months

  41. Number of Patients Categorized by Type of Treatment for SMA

    Treatments included:

    • Nusinersen
    • Risdiplam
    • Onasemnogene abeparvovec
    • Palivizumab
    • Influenza vaccine
    • Meningococcal vaccine
    • High protein shakes

    Measured: Up to 6 years and 4 months

  42. Number of Nusinersen Doses

    Nusinersen doses included loading and maintenance doses.

    Measured: Up to 6 years and 4 months

  43. Risdiplam Dose

    Risdiplam dose included starting dose and dose changes.

    Measured: Up to 6 years and 4 months

  44. Palivizumab Dose

    Measured: Up to 6 years and 4 months

  45. Number of High Protein Shakes per Day

    Measured: Up to 6 years and 4 months

  46. Number of Months of Taking High Protein Shakes

    Measured: Up to 6 years and 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2024
  2. Study start5 Jul 2023
  3. Primary completion20 Nov 2023
  4. Study completion20 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
69 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06632730
Sponsor's protocol ID
COAV101A1ES05
Status last verified
Oct 2024
First submitted
7 Oct 2024
Last updated
9 Oct 2024
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Spinal Muscular Atrophy Type I and Spinal Muscular Atrophy Type II, run by Novartis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cost per Year of Use of Resources for Medical Visits (time frame: Up to 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in